Controls severe or incapacitating allergic conditions. ANDA 40803, held by Mylan Laboratories. Dexamethasone Sodium Phosphate.
As of Nov 20, 2026, ANDA 40803 (Dexamethasone Sodium Phosphate), held by Mylan Laboratories, was first approved by FDA on Aug 29, 2008, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE A. By intravenous or intramuscular injection when oral therapy is not feasible 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jul 3, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 29, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters